Literature DB >> 2784744

Natural autoantibodies in the serum of healthy women--a five-year follow-up.

O Yadin1, B Sarov, L Naggan, H Slor, Y Shoenfeld.   

Abstract

Autoantibodies are often found among healthy individuals. The significance of these findings, regarding the potential development of overt autoimmune disease and the severity of such an eventuality, is as yet unclear. In order to elucidate these issues 506 healthy women were screened and 60 women of child-bearing age were found to posses high titres of various anti-nuclear antibodies. After a 5-year follow-up, 57 of these 60 women were found to have autoantibodies to a variety of autoantigens. Seven of the women had some symptoms that could be associated with the presence of the antibodies (i.e. arthritis, multiple abortions, Raynaud's phenomenon), however, none exhibited overt clinical signs of an autoimmune disease. Our study may point to the fact that in normal subjects (women aged 22-44 years) high titres of natural autoantibodies are not necessarily indicative of a high risk of developing an overt autoimmune condition, at least for a follow-up period of 5 years.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784744      PMCID: PMC1541956     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus.

Authors:  A J Swaak; L A Aarden; L W Statius van Eps; T E Feltkamp
Journal:  Arthritis Rheum       Date:  1979-03

2.  Autoantibodies in healthy subjects of different age groups.

Authors:  J P Pandey; H H Fudenberg; S K Ainsworth; C B Loadholt
Journal:  Mech Ageing Dev       Date:  1979-07       Impact factor: 5.432

3.  Anti-DNA binding activity in systemic lupus erythematosus, rheumatoid arthritis, and normal subjects.

Authors:  P Pottgen; R Salvatore
Journal:  Clin Chem       Date:  1979-07       Impact factor: 8.327

4.  Serum DNA binding activity in healthy subjects and in rheumatic disease.

Authors:  P Hasselbacher; E C LeRoy
Journal:  Arthritis Rheum       Date:  1974 Jan-Feb

5.  Significance of persisting serologic abnormalities in SLE.

Authors:  R W Lightfoot; G R Hughes
Journal:  Arthritis Rheum       Date:  1976 Sep-Oct

6.  Clinical significance of antibodies to ribonucleoprotein.

Authors:  M L Cohen; B Dawkins; R L Dawkins; E T Owen
Journal:  Ann Rheum Dis       Date:  1979-02       Impact factor: 19.103

7.  Family study of systemic lupus erythematosus: analysis of the clinical history, skin immunofluorescence, and serologic parameters.

Authors:  M B Lowenstein; N F Rothfield
Journal:  Arthritis Rheum       Date:  1977 Sep-Oct

8.  Anti-Rnp antibodies in chronic liver diseases.

Authors:  F Konikoff; Y Shoenfeld; D A Isenberg; I Barrison; T Sobe; E Theodor; H Slor
Journal:  Clin Exp Rheumatol       Date:  1987 Oct-Dec       Impact factor: 4.473

9.  A long-term follow up of patients with autoimmune thyroid disease.

Authors:  M S Khangure; P R Dingle; J Stephenson; T Bird; R Hall; D C Evered
Journal:  Clin Endocrinol (Oxf)       Date:  1977-01       Impact factor: 3.478

10.  Chronic idiopathic thrombocytopenic purpura. A familial immunodeficiency syndrome?

Authors:  M J Stuart; R H Tomar; M L Miller; F R Davey
Journal:  JAMA       Date:  1978-03-06       Impact factor: 56.272

View more
  9 in total

1.  Stability of natural self-reactive antibody repertoires during aging.

Authors:  S Lacroix-Desmazes; L Mouthon; S V Kaveri; M D Kazatchkine; M E Weksler
Journal:  J Clin Immunol       Date:  1999-01       Impact factor: 8.317

2.  Geographical differences in autoantibodies and anti-infectious agents antibodies among healthy adults.

Authors:  Yinon Shapira; Bat-Sheva Poratkatz; Boris Gilburd; Ori Barzilai; Maya Ram; Miri Blank; Staffan Lindeberg; Johan Frostegård; Juan-Manuel Anaya; Nicola Bizzaro; Luis J Jara; Jan Damoiseaux; Yehuda Shoenfeld; Nancy Agmon Levin
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

3.  Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.

Authors:  S Kaveri; T Vassilev; V Hurez; R Lengagne; C Lefranc; S Cot; P Pouletty; D Glotz; M D Kazatchkine
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

4.  Antinuclear antibodies and breast implants.

Authors:  H N Claman; A D Robertson
Journal:  West J Med       Date:  1994-03

5.  Reproductive and hormonal risk factors for antinuclear antibodies (ANA) in a representative sample of U.S. women.

Authors:  Christine G Parks; Frederick W Miller; Minoru Satoh; Edward K L Chan; Zhanna Andrushchenko; Linda S Birnbaum; Todd A Jusko; Grace E Kissling; Mehul D Patel; Kathryn M Rose; Clarice Weinberg; Darryl C Zeldin; Dale P Sandler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-01       Impact factor: 4.254

6.  Association between Vitamin D Deficiency and Antinuclear Antibodies in Middle-Aged and Older U.S. Adults.

Authors:  Helen C S Meier; Dale P Sandler; Eleanor M Simonsick; Christine G Parks
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-08-19       Impact factor: 4.254

7.  Sex differences in the association between antinuclear antibody positivity with diabetes and multimorbidity in older adults: Results from the Baltimore Longitudinal Study of Aging.

Authors:  Helen C S Meier; Dale P Sandler; Eleanor M Simonsick; Nan-Ping Weng; Christine G Parks
Journal:  Exp Gerontol       Date:  2020-03-05       Impact factor: 4.032

8.  Is there a predisposition for the development of autoimmune diseases in patients with fibromyalgia? Retrospective analysis with long term follow-up.

Authors:  Ina Kötter; Daniela Neuscheler; Ilhan Günaydin; Dorothee Wernet; Reinhild Klein
Journal:  Rheumatol Int       Date:  2007-07-20       Impact factor: 2.631

9.  Antinuclear antibodies and mortality in the National Health and Nutrition Examination Survey (1999-2004).

Authors:  Gregg E Dinse; Christine G Parks; Clarice R Weinberg; Helen C S Meier; Caroll A Co; Edward K L Chan; Frederick W Miller
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.